Table 2.
Number (percentage) of patients reporting nonlaboratory sorafenib related adverse events by CTCAE grading.
| Adverse events | Any n (%) | Grade 1 n (%) | Grade 2 n (%) | Grade 3 n (%) | Grade 4 n (%) |
|---|---|---|---|---|---|
| HFSR | 182 (77.4) | 57 (24.3) | 80 (34.0) | 45 (19.1) | — |
| Alopecia | 156 (66.4) | 139 (59.1) | 17 (7.2) | — | — |
| Rash | 124 (52.8) | 63 (26.8) | 49 (20.9) | 12 (5.1) | — |
| Diarrhea | 100 (42.6) | 48 (20.4) | 41 (17.4) | 11 (4.7) | — |
| Fatigue | 102 (43.4) | 95 (40.4) | 7 (3.0) | — | — |
| Voice change | 46 (19.6) | 42 (17.9) | 4 (1.7) | — | — |
| Dental ulcer | 26 (11.1) | 14 (6.0) | 12 (5.1) | — | — |
| Hypertension | 29 (12.3) | 15 (6.4) | 13 (5.5) | 1 (0.4) | — |
Abbreviations: CTCAE, common terminology criteria for adverse events; HFSR, hand-foot-skin reaction.